acv1 phase 2a results, page-3

There can be no question that reasons exist for concern with respect to Metabolic management based on what happened with the AOD9604 two-year debacle.

On the other hand, this is NOT AOD9604 we're now talking about.

ACV1 is a drug that has had a clear and unambiguous pre-clinical history, unlike AOD9604. ACV1 has been proven efficacious in a number of animal models by a large number of independent researchers.

Moreover, the company's behavior since the completion of treatment in the recent trial is entirely consistent with a perceived successful outcome.

There is NO reason known to me to doubt the success of the 2A trial just completed. That's not to say that it is in the bag, it's just to say that the risk has been largely mitigated.

Then there is the fact that Metabolic has demonstrated efficacy of their oral version of ACV1. This greatly enhances the consumer acceptability and potential range of usages for the drug.

Finally, it is my opnion, based on reading multiple research reports published in the scientific literature, that ACV1 has potential application for a large number of indications beyond sciatica, shingles and diabetic neuropathy.

For example, last December in an article appearing in Toxicon, entitled "Trapeutic Applications of Conotoxins that Target the Neuronal Nicotinic Acetylcholine Receptor", the authors mention that "ACV1 will be targeted initially for the treatment of sciatica, shingles and diabetic neuropathy." Note that word "initially".

The authors also mention the potential use of ACV1 in the treatment of multiple sclerosis. In other papers I have read, ACV1 has been suggested as a possible treatment for phantom limb pain, HIV related conditions, and post operative pain, just to name a few from memory.

It would be a big mistake to paint ACV1 with the AOD9604 brush, a mistake that might well blind an individual to a major market opportunity.